Want to see IN:ASTRAZEN full AI Analyst Report?
Top Page
AstraZeneca Pharma India Limited
(ASTRAZEN)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹7,085.00
▼(-15.97% Downside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by the FY2026 cash flow collapse and profitability compression, alongside very weak technical momentum (below all major moving averages with oversold indicators). A strong balance sheet and solid revenue growth provide some support, but the high P/E and low yield keep valuation from offsetting these risks.
Positive Factors
Revenue Growth
Sustained revenue expansion indicates continued demand for the company’s prescription portfolio and provides a durable base for future growth, particularly if specialty therapies continue gaining physician and institutional adoption.
Negative Factors
Sharp Cash Flow Deterioration
The steep reduction in operating and free cash flow weakens internal funding capacity and raises concerns about working-capital volatility or higher cash usage. Persistent weak conversion could constrain reinvestment and shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue expansion indicates continued demand for the company’s prescription portfolio and provides a durable base for future growth, particularly if specialty therapies continue gaining physician and institutional adoption.
Read all positive factors
AstraZeneca Pharma India Limited (ASTRAZEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹178.03B
Dividend Yield0.51%
Average Volume (3M)602.00
Price to Earnings (P/E)104.7
Beta (1Y)0.65
Revenue Growth31.10%
EPS Growth-7.49%
CountryIN
Employees760
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)67.85
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)22.24
Price to Sales (P/S)8.53
P/FCF Ratio6.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AstraZeneca Pharma India Limited Business Overview & Revenue Model
Company Description
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The comp...
How the Company Makes Money
AstraZeneca Pharma India Limited primarily makes money by selling prescription pharmaceutical products in India. Its key revenue stream is domestic sales of branded medicines from its therapeutic portfolio (notably in specialty care areas such as ...
AstraZeneca Pharma India Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
86
Very Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.32B | 22.76B | 17.13B | 12.96B | 10.03B | 8.06B |
| Gross Profit | 7.64B | 6.02B | 7.13B | 6.22B | 5.78B | 4.48B |
| EBITDA | 2.42B | 2.85B | 1.98B | 2.36B | 1.51B | 1.01B |
| Net Income | 1.70B | 1.88B | 1.16B | 1.62B | 992.90M | 616.00M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 19.89B | 15.18B | 10.78B | 9.85B | 8.57B |
| Cash, Cash Equivalents and Short-Term Investments | 4.48B | 4.49B | 5.53B | 5.06B | 5.00B | 4.48B |
| Total Debt | 0.00 | 1.11B | 357.30M | 45.90M | 72.10M | 86.30M |
| Total Liabilities | -8.73B | 11.16B | 7.48B | 3.66B | 3.96B | 3.45B |
| Stockholders Equity | 8.73B | 8.73B | 7.70B | 7.12B | 5.89B | 5.11B |
Cash Flow | ||||||
| Free Cash Flow | -660.20M | 32.10M | 636.10M | 171.10M | 497.70M | 911.80M |
| Operating Cash Flow | -657.30M | 68.20M | 653.60M | 278.70M | 582.90M | 1.01B |
| Investing Cash Flow | 135.40M | -33.40M | 308.00M | 217.40M | 181.10M | 47.40M |
| Financing Cash Flow | -845.60M | -919.00M | -655.90M | -443.80M | -244.80M | -94.60M |
AstraZeneca Pharma India Limited Technical Analysis
Negative
8431.70
Price Trends
7994.50
Negative
8199.41
Negative
8452.16
Negative
Market Momentum
-250.72
Positive
21.81
Positive
5.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Negative. The current price of 8431.7 is above the 20-day moving average (MA) of 7739.18, above the 50-day MA of 7994.50, and below the 200-day MA of 8452.16, indicating a bearish trend. The MACD of -250.72 indicates Positive momentum. The RSI at 21.81 is Positive, neither overbought nor oversold. The STOCH value of 5.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTRAZEN.
AstraZeneca Pharma India Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹980.26B | 29.66 | ― | 0.69% | -0.92% | -41.75% | |
69 Neutral | ₹989.73B | 17.94 | ― | 0.76% | 28.19% | 49.25% | |
69 Neutral | ₹4.56T | 38.09 | ― | 0.82% | 11.41% | 16.62% | |
63 Neutral | ₹1.91T | 78.37 | ― | 0.30% | 32.85% | 8.94% | |
60 Neutral | ₹693.14B | 39.48 | ― | 0.24% | 32.94% | 138.54% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹178.03B | 104.74 | ― | 0.35% | 31.10% | -7.49% |
* General Sector Average
IN:ASTRAZEN
AstraZeneca Pharma India Limited
7,106.25
-1,325.51
-15.72%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,177.80
-77.24
-6.15%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,517.40
597.86
31.15%
IN:LUPIN
Lupin Limited
2,175.00
295.53
15.72%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,920.10
340.48
21.55%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
5,035.00
1,507.39
42.73%
AstraZeneca Pharma India Limited Corporate Events
Delhi High Court Grants AstraZeneca India Interim Relief in NPPA Drug Pricing Dispute
Aug 25, 2026
AstraZeneca Pharma India Limited has informed the stock exchanges that the Delhi High Court has granted an interim stay on a National Pharmaceutical Pricing Authority demand notice alleging overcharging on Betaloc-50 tablets. The notice claimed th...
AstraZeneca Pharma India Discloses Unsolicited ESG Rating from Crisil
Aug 24, 2026
AstraZeneca Pharma India Limited disclosed that Crisil ESG Ratings Analytics has assigned it an Environmental, Social and Governance score of 57, based solely on publicly available information. The company clarified it did not engage Crisil for t...
AstraZeneca Pharma India Plans Virtual Meeting With Institutional Investor
Aug 21, 2026
AstraZeneca Pharma India Limited has scheduled a virtual one-on-one meeting with an institutional investor on August 26, 2026, in line with regulatory requirements for disclosure of analyst and investor interactions. The company notes that the dat...
AstraZeneca Pharma India Schedules Virtual Meet with Institutional Investor
Aug 15, 2026
AstraZeneca Pharma India has announced that it will hold a virtual one-on-one meeting with an institutional investor on August 19, 2026, as part of its ongoing engagement with the analyst and investor community. The company noted that the schedule...
AstraZeneca Pharma India Clears Dividend and Board Moves at 47th AGM
Aug 10, 2026
AstraZeneca Pharma India Limited held its 47th Annual General Meeting on August 10, 2026 via video conferencing, after a brief delay due to lack of quorum. Shareholders considered routine corporate matters, including adoption of the FY 2026 financ...
AstraZeneca Pharma India posts 30% revenue surge in Q1 FY2026–27 driven by core therapies
Aug 10, 2026
AstraZeneca Pharma India reported a strong start to FY2026–27, with total revenue from operations rising 30% year-on-year to INR 6,828 million in the quarter ended June 30, 2026. The growth was driven by robust performance across its core th...
AstraZeneca Pharma India Wins New Breast Cancer Approval for Enhertu
Aug 8, 2026
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization to import Trastuzumab Deruxtecan 100mg/5mL, marketed as Enhertu, for an additional indication in India. The approval covers adjuvant trea...
AstraZeneca Pharma India Confirms SEBI-Compliant Dematerialization for Q1 FY27
Jul 29, 2026
AstraZeneca Pharma India Limited has reported that its registrar and transfer agent, Integrated Registry Management Services, has certified compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quar...
AstraZeneca Pharma India Surrenders Factory License as It Exits Manufacturing Site
Jun 3, 2026
AstraZeneca Pharma India has announced that its Board’s Administrative Committee has approved the surrender of the company’s factory license, which was valid until December 31, 2026, to the Department of Factories, Boilers, Industrial ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.